Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 3 for:    PTI-808 | Cystic Fibrosis

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03140527
Recruitment Status : Completed
First Posted : May 4, 2017
Last Update Posted : April 30, 2020
Sponsor:
Information provided by (Responsible Party):
Proteostasis Therapeutics, Inc.

Tracking Information
First Submitted Date  ICMJE April 27, 2017
First Posted Date  ICMJE May 4, 2017
Last Update Posted Date April 30, 2020
Actual Study Start Date  ICMJE April 10, 2017
Actual Primary Completion Date February 27, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 27, 2018)
  • Part 1 SAD and MAD HV: Safety and tolerability measured by number of subjects who experience adverse events and potential clinically significant changes in safety labs, electrocardiograms (ECGs), physical examinations, and vital signs [ Time Frame: baseline to up to 14 days ]
  • Part 1 SAD: Apparent terminal half-life (t1/2) of single oral dose [ Time Frame: through 72-hours post dose ]
  • Part 1 SAD: Time to reach maximum plasma concentration (Tmax) of single oral dose [ Time Frame: through 72-hours post dose ]
  • Part 1 SAD: Maximum plasma concentration (Cmax) of single oral dose [ Time Frame: through 72-hours post dose ]
  • Part 1 SAD: Area under the concentration-time curve from time 0 to 24 hours post administration (AUC0-24) of a single oral dose [ Time Frame: through 72-hours post dose ]
  • Part 1 SAD: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUC0-last) of a single oral dose [ Time Frame: through 72-hours post dose ]
  • Part 1 SAD: AUC from time 0 to infinity (AUC0-inf) [ Time Frame: through 72-hours post dose ]
    using noncompartmental methods as appropriate of single dose
  • Part 1 MAD HV: Apparent terminal half-life (t1/2) of multiple oral doses [ Time Frame: through 72-hours post last dose ]
  • Part 1 MAD HV: Time to reach maximum plasma concentration (Tmax) of multiple oral doses [ Time Frame: through 72-hours post last dose ]
  • Part 1 MAD HV: Maximum plasma concentration (Cmax) of multiple oral doses [ Time Frame: through 72-hours post last dose ]
  • Part 1 MAD HV: Area under the concentration-time curve from time 0 to 24 hours post administration (AUC0-24) of multiple oral doses [ Time Frame: through 72-hours post dose ]
  • Part 1 MAD HV: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUClast) of multiple oral doses [ Time Frame: through 72-hour post last dose ]
  • Part 1 MAD HV: AUC from time 0 to infinity (AUC0-inf) of multiple oral doses [ Time Frame: through 72-hour post last dose ]
    using noncompartmental methods as appropriate of multiple oral doses
  • Part 1 MAD HV: Cumulative amount of PTI-801 excreted unchanged in urine (Ae) as appropriate of multiple oral doses [ Time Frame: through 24-hour post last dose ]
  • Part 1 MAD HV: Cumulative amount of PTI-801 unchanged in renal clearance (CLR) as appropriate of multiple oral doses [ Time Frame: through 24-hour post last dose ]
  • Part 1 FE: Time to reach maximum plasma concentration (Tmax) [ Time Frame: through 72-hour post last dose ]
  • Part 1 FE :Maximum plasma concentration (Cmax) [ Time Frame: through 72-hour post last dose ]
  • Part 1 FE: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUCt) [ Time Frame: through 72-hour post last dose ]
  • Part 1 FE: AUC from time 0 to infinity (AUC0-inf) [ Time Frame: through 72-hour post last dose ]
  • Part 1 DDI: Safety and tolerability measured by number of subjects who experience adverse events and potential clinically significant changes in safety labs, electrocardiograms (ECGs), physical examinations, and vital signs [ Time Frame: baseline through 7 days post last dose ]
  • Part 1 DDI: Maximum plasma concentration (Cmax) of caffeine, bupropion, and midazolam with and without multiple oral doses of PTI-801 [ Time Frame: through 72-hours post dose ]
  • Part 1 DDI: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUClast) of caffeine, bupropion, and midazolam with and without multiple oral doses of PTI-801 [ Time Frame: through 72-hours post dose ]
  • Part 1 DDI: Area under the concentration-time curve from time 0 to infinity (AUCinf) of caffeine, bupropion, and midazolam with and without multiple oral doses of PTI-801 [ Time Frame: through 72-hours post dose ]
  • Part 2 CF: Safety and tolerability measured by number of subjects who experience adverse events and potential clinically significant changes in safety labs, electrocardiograms (ECGs), physical examinations, and vital signs [ Time Frame: baseline through Day 21 ]
Original Primary Outcome Measures  ICMJE
 (submitted: May 2, 2017)
  • SAD and MAD: Safety and tolerability measured by number of subjects who experience adverse events and potential clinically significant changes in safety labs, electrocardiograms (ECGs), physical examinations, and vital signs [ Time Frame: baseline to up to 14 days ]
  • SAD:Apparent terminal half-life (t1/2) of single oral dose [ Time Frame: through 72-hours post dose ]
  • SAD:Time to reach maximum plasma concentration (Tmax) of single oral dose [ Time Frame: through 72-hours post dose ]
  • SAD:Maximum plasma concentration (Cmax) of single oral dose [ Time Frame: through 72-hours post dose ]
  • SAD: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUCt) of single oral dose [ Time Frame: through 72-hours post dose ]
  • SAD:AUC from time 0 to infinity (AUC0-inf) [ Time Frame: through 72-hours post dose ]
    using noncompartmental methods as appropriate of single dose
  • MAD:Apparent terminal half-life (t1/2) of multiple oral doses [ Time Frame: through 72-hours post last dose ]
  • MAD:Time to reach maximum plasma concentration (Tmax) of multiple oral doses [ Time Frame: through 72-hours post last dose ]
  • MAD:Maximum plasma concentration (Cmax) of multiple oral doses [ Time Frame: through 72-hours post last dose ]
  • MAD:Area under the concentration-time curve from time 0 to time of last measurable concentration (AUCt) of multiple oral doses [ Time Frame: through 72-hour post last dose ]
  • MAD:AUC from time 0 to infinity (AUC0-inf) of multiple oral doses using noncompartmental methods as appropriate of multiple oral doses [ Time Frame: through 72-hour post last dose ]
  • MAD:cumulative amount of PTI-801 excreted unchanged in urine (Ae) as appropriate of multiple oral doses [ Time Frame: through 24-hour post last dose ]
  • MAD:cumulative amount of PTI-801 unchanged in renal clearance (CLR) as appropriate of multiple oral doses [ Time Frame: through 24-hour post last dose ]
  • FE: Time to reach maximum plasma concentration (Tmax) [ Time Frame: through 72-hour post last dose ]
  • FE:Maximum plasma concentration (Cmax) [ Time Frame: through 72-hour post last dose ]
  • FE:Area under the concentration-time curve from time 0 to time of last measurable concentration (AUCt) [ Time Frame: through 72-hour post last dose ]
  • FE:AUC from time 0 to infinity (AUC0-inf) [ Time Frame: through 72-hour post last dose ]
    using noncompartmental methods as appropriate of single dose
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 17, 2019)
  • Part 1 FE: Safety and tolerability measured by number of subjects who experience adverse events and potential clinically significant changes in safety labs, electrocardiograms (ECGs), physical examinations, and vital signs [ Time Frame: baseline through 7 days post last dose ]
  • Part 1 DDI: Apparent terminal half-life (t1/2) of multiple oral doses of PTI-801 with and without caffeine, bupropion, and midazolam [ Time Frame: through 72-hours post dose ]
  • Part 1 DDI: Time to reach maximum plasma concentration (Tmax) of the metabolites of caffeine, bupropion, and midazolam after single oral doses of caffeine, bupropion, midazolam, and with and without multiple oral doses of PTI-801 [ Time Frame: through 72-hours post dose ]
  • Part 1 DDI: Maximum plasma concentration (Cmax) of the metabolites of caffeine, bupropion, and midazolam after single oral doses of caffeine, bupropion, midazolam, and with and without multiple oral doses of PTI-801 [ Time Frame: through 72-hours post dose ]
  • Part 1 DDI: AUClast of the metabolites of caffeine, bupropion, and midazolam after single oral doses of caffeine, bupropion, midazolam, and with and without multiple oral doses of PTI-801 [ Time Frame: through 72-hours post dose ]
  • Part 1 DDI: Area under the concentration-time curve from time 0 to 24 hours post administration (AUC0-24) of multiple oral doses of PTI-801 with and without caffeine, bupropion, and midazolam [ Time Frame: through 72-hours post dose ]
  • Part 1 DDI: Metabolite over parent ratio of Cmax of single oral doses of the metabolites of caffeine, bupropion, and midazolam after single oral doses of caffeine, bupropion, midazolam, and with and without multiple oral doses of PTI-801 [ Time Frame: through 72-hours post dose ]
  • Part 1 DDI: Metabolite over parent ratio of AUClast of the metabolites of caffeine, bupropion, and midazolam after single oral doses of caffeine, bupropion, midazolam, and with and without multiple oral doses of PTI-801 [ Time Frame: through 72-hours post dose ]
  • Part 1 DDI: Time to reach maximum plasma concentration (Tmax) of multiple oral doses of PTI-801 with and without caffeine, bupropion, and midazolam [ Time Frame: through 72-hours post dose ]
  • Part 1 DDI: Maximum plasma concentration (Cmax) of multiple oral doses of PTI-801 with and without caffeine, bupropion, and midazolam [ Time Frame: through 72-hours post dose ]
  • Part 1 DDI: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUClast) of multiple oral doses of PTI-801 with and without caffeine, bupropion, and midazolam [ Time Frame: through 72-hours post dose ]
  • Part 2 CF: Time to reach maximum plasma concentration (Tmax) [ Time Frame: Day 1 through Day 15 ]
  • Part 2 CF: Maximum plasma concentration (Cmax) [ Time Frame: Day 1 through Day 15 ]
  • Part 2 CF: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUClast) [ Time Frame: Day 1 through Day 15 ]
  • Part 2 CF: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUClast) of multiple oral doses of PTI-808 with PTI-801 [ Time Frame: Day 1 through Day 15 ]
  • Part 2 CF: change in forced expiratory volume in one second (FEV1) over time [ Time Frame: baseline through Day 21 ]
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures
 (submitted: January 17, 2019)
  • Part 1 SAD, MAD HV, and FE: The effect of PTI-801 on the QT interval as measured by holter monitoring [ Time Frame: baseline through 7 days post last dose ]
  • Part 1: change in nasal epithelial mRNA and protein expression over time [ Time Frame: baseline through 7 days post last dose ]
  • Part 2 CF: change in sweat chloride over time [ Time Frame: baseline through Day 21 ]
  • Part 2 CF: change in nasal epithelial mRNA and protein expression over time [ Time Frame: baseline through Day 21 ]
  • Part 2 CF: change in weight and BMI over time [ Time Frame: baseline through Day 21 ]
  • Part 2 CF: change in blood glucose over time [ Time Frame: baseline through Day 21 ]
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis
Official Title  ICMJE A Multi-Center, Randomized, Placebo-Controlled, Phase 1, Two-Part Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis
Brief Summary

This trial will consist of two parts: Part 1 and Part 2. Part 1 will enroll adult healthy volunteers (HV) into four treatment groups. The first group will enroll HV into a single ascending dose (SAD) treatment group consisting of three cohorts. The second group will enroll HV into a multiple ascending dose (MAD) treatment group consisting of three cohorts. The third group will enroll HV into a food effect (FE) treatment group consisting of one cohort. The fourth group will enroll HV into a drug-drug interactions (DDI) treatment group consisting of one cohort. Approximately 76 subjects will be enrolled in Part 1.

Part 2 Cohorts 1 through 3 will enroll adult subjects with cystic fibrosis (CF) currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months. Part 2 Cohorts 4 and Cohort 5 will enroll adult subjects with CF not currently receiving cystic fibrosis conductance regulator (CFTR) modulator therapy within 30 days prior to Day 1. Part 2 Cohort 6 will enroll adult subjects with cystic fibrosis on stable tezacaftor/ivacaftor background therapy. Approximately 104 subjects will be enrolled in Part 2.

Detailed Description

PART 1 The SAD treatment group is comprised of three cohorts where HV will be randomized to either PTI-801 or placebo. The MAD treatment group is comprised of three cohorts where subjects will be randomized to receive either PTI-801 or placebo once daily (QD) for a total of 7 days. HV will participate in a FE treatment group ,the FE treatment group is comprised of one cohort where subjects will be randomized to receive an initial single dose of PTI-801 either after an overnight fast of at least 10 hours (fasted group) or after an overnight fast of at least 10 hours followed by the consumption of a high fat high and high calorie meal (fed group). A set of HV will participate in a DDI treatment group. The DDI treatment group is comprised of one cohort where subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo.

PART 2 Part 2 is comprised of a MAD treatment group with three cohorts, a co-administration group with two cohorts and a treatment group with one cohort.

Following the conclusion of the complementary HV MAD Cohort in Part 1, a set of adult subjects diagnosed with CF currently on a stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days.

Following the conclusion of CF MAD Cohort 1 in Part 2, a set of adult subjects diagnosed with CF not currently receiving or have received background CFTR modulator therapy for a minimum of 30 days prior to Day 1 will participate in the Part 2 CF PTI-801 and PTI-808 co-administration cohort. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD for a total of 14 days.

Following the conclusion of the CF MAD Cohort 1 in Part 2, a set of adult subjects diagnosed with CF currently on a stable tezacaftor/ivacaftor background therapy for a minimum of one month will participate in the Part 2 complementary CF cohort. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE
  • Healthy Volunteer
  • Cystic Fibrosis
Intervention  ICMJE
  • Drug: PTI-801
    Active
  • Drug: Placebo
    Placebo
  • Drug: PTI-808
    Active
Study Arms  ICMJE
  • Active Comparator: SAD HV PTI-801 Active - Complete
    The safety, tolerability, and pharmacokinetic profile of PTI-801 will be evaluated following a single dose of PTI-801. Three cohorts are planned for evaluation where subjects will be randomized to PTI-801 or placebo.The subjects will be followed for 7 days post dose.
    Intervention: Drug: PTI-801
  • Placebo Comparator: SAD HV PTI-801 Placebo - Complete
    The safety, tolerability, and pharmacokinetic profile of PTI-801 will be evaluated following a single dose of PTI-801. Three cohorts are planned for evaluation where subjects will be randomized to PTI-801 or placebo.The subjects will be followed for 7 days post dose.
    Intervention: Drug: Placebo
  • Active Comparator: MAD HV PTI-801 Active - Complete
    Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-801 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 10, 12 and 14.
    Intervention: Drug: PTI-801
  • Placebo Comparator: MAD HV PTI-801 Placebo - Complete
    Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-801 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 10, 12 and 14.
    Intervention: Drug: Placebo
  • Active Comparator: FE HV PTI-801 Active - Complete
    Following the conclusion of SAD groups and after sufficient review of study data and approval by the SRC, a third set of healthy adult subjects will participate in the Food Effect cohort. Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
    Intervention: Drug: PTI-801
  • Active Comparator: DDI HV PTI-801 Active - Complete
    Following the conclusion of HV MAD Cohort 2 and after sufficient review of study data and approval by the SRC, a fourth set of healthy adult subjects will participate in the Drug-Drug Interactions cohort. Subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo. Subjects will remain in clinic until Day 20. A follow up visit will occur on Day 24.
    Intervention: Drug: PTI-801
  • Placebo Comparator: DDI HV PTI-801 Placebo - Complete
    Following the conclusion of HV MAD Cohort 2 and after sufficient review of study data and approval by the SRC, a fourth set of healthy adult subjects will participate in the Drug-Drug Interactions cohort. Subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo. Subjects will remain in clinic until Day 20. A follow up visit will occur on Day 24.
    Intervention: Drug: Placebo
  • Active Comparator: MAD Cohort 1-3 CF PTI-801 Active - Complete
    Adult subjects diagnosed with CF currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. The CF MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days. A follow up visit will occur on Day 21.
    Intervention: Drug: PTI-801
  • Placebo Comparator: MAD Cohort 1-3 CF PTI-801 Placebo - Complete
    Adult subjects diagnosed with CF currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. The CF MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days. A follow up visit will occur on Day 21.
    Intervention: Drug: Placebo
  • Active Comparator: Cohort 4 CF PTI-801 Active co-admin PTI-808 Active - Complete
    Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 4. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
    Interventions:
    • Drug: PTI-801
    • Drug: PTI-808
  • Placebo Comparator: Cohort 4 CF PTI-801 Placebo co-admin PTI-808 Placebo- Complete
    Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 4. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
    Interventions:
    • Drug: Placebo
    • Drug: Placebo
  • Active Comparator: Cohort 5 CF PTI-801 Active co-admin with PTI-808 Active
    Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 5. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
    Interventions:
    • Drug: PTI-801
    • Drug: PTI-808
  • Placebo Comparator: Cohort 5 CF PTI-801 Placebo co-admin with PTI-808 Placebo
    Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 5. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
    Interventions:
    • Drug: Placebo
    • Drug: Placebo
  • Active Comparator: Cohort 6 CF PTI-801 Active
    Adult subjects diagnosed with CF currently on stable tezacaftor/ivacaftor background therapy for a minimum of one month will participate in the Part 2 complementary CF MAD cohort. Subjects will be randomized to receive either PTI-801 or placebo QD.
    Intervention: Drug: PTI-801
  • Placebo Comparator: Cohort 6 CF PTI-801 Placebo
    Adult subjects diagnosed with CF currently on stable tezacaftor/ivacaftor background therapy for a minimum of one month will participate in the Part 2 complementary CF MAD cohort. Subjects will be randomized to receive either PTI-801 or placebo QD.
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 28, 2020)
171
Original Estimated Enrollment  ICMJE
 (submitted: May 2, 2017)
60
Actual Study Completion Date  ICMJE February 27, 2020
Actual Primary Completion Date February 27, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Part 1 Inclusion Criteria:

  • Adults age 18 to 55 years old, inclusive, at the time of informed consent.
  • Body mass index (BMI) ≥18 to <30 kg/m2.
  • Subject must be a nonsmoker and a nontobacco user for a minimum of 30 days prior to screening and for the duration of the study.

Part 1 Exclusion Criteria:

  • History or current evidence of any clinically significant cardiac, endocrinologic,hematologic, hepatobiliary, immunologic, metabolic, urologic, pulmonary, neurologic,dermatologic, psychiatric, renal, or other major disease, as determined by the investigator.
  • Presence of prolonged QT/ Corrected QT Interval (QTc) interval with Fridericia's correction formula (QTcF) >450 msec at screening.
  • Abnormal liver function as defined by aspartate aminotransferase (AST), alanine aminotransferase (ALT) or bilirubin > upper limit of the normal range.
  • Abnormal renal function at screening defined as: Creatinine clearance <80 mL/min using the Cockcroft-Gault equation.
  • Participation in another clinical trial or treatment with an investigational agent within 30 days or 5 half-lives, whichever is longer, prior to Study Day 1.
  • History of cancer within the past 5 years (excluding nonmelanoma skin cancer).
  • History or current evidence of alcohol or drug abuse or dependence within 12 months of screening as determined by the investigator.
  • Positive urine screen for prohibited drugs (cocaine, cannabinoids, nicotine [urine cotinine is the detection mechanism for nicotine], opiates, barbiturates, amphetamines, and benzodiazepines) or positive alcohol test at screening.
  • Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (HCVAb).
  • Has donated blood within 3 months of screening or plans to donate blood within 3 months of study completion.

Part 1 HV DDI Cohort Additional Exclusion Criteria:

  • Concomitant use of known strong or moderate inhibitors or inducers of CYP1A2, CYP2B6, and CYP3A4 within 14 days or 5 half-lives (whichever is longer) prior to Day 1 and through the last PK sampling point on Day 20
  • Use of grapefruit- or Seville orange-containing products within 48 hours prior to Day 1 and through the last PK sampling point on Day 20
  • Use of alcohol- or caffeine-containing products within 48 hours prior to Day 1 and through the last PK sampling point on Day 20

Part 2 Inclusion Criteria:

  • Confirmed diagnosis of CF with the F508del/F508del genotype on record, along with clinical findings consistent with CF such as chronic sinopulmonary disease or gastrointestinal/nutritional abnormalities
  • Forced expiratory volume in 1 second (FEV1) 40-90% predicted, inclusive
  • Non-smoker and non-tobacco user for a minimum of 30 days prior to screening

Part 2 Cohorts 1-3 Additional Inclusion Criterion:

  • Stable on ivacaftor/lumacaftor dosing for both label indication and per label dosing for a minimum of 3 months at the time of dosing

Part 2 Cohort 6 Additional Inclusion Criterion:

  • Stable on tezacaftor/ivacaftor dosing for both label indication and per label dosing for a minimum of 1 month at the time dosing

Part 2 Exclusion Criteria:

  • Participation in another clinical trial or treatment with an investigational agent within 28 days or 5 half-lives, whichever is longer, prior to Study Day 1
  • History of cancer within the past 5 years (excluding cervical cancer in situ with curative therapy for at least one year prior to screening and non-melanoma skin cancer)
  • History of organ transplantation
  • Hospitalization, sinopulmonary infection, CF exacerbation, or other clinically significant infection or illness (as determined by the investigator) requiring an increase or addition of medication, such as antibiotics or corticosteroids, within 14 days of Day 1
  • Initiation of any new chronic therapy (e.g., ibuprofen, hypertonic saline, azithromycin, Pulmozyme®, Cayston®, TOBI®)) or any change in chronic therapy (excluding pancreatic enzyme replacement therapy) within 28 days prior to Day 1
  • History or current evidence of alcohol or drug abuse or dependence within 12 months of screening as determined by the investigator
  • Pregnant or nursing women

Part 2 Cohort's 4 and 5 Additional Exclusion Criterion:

  • Currently taking or has taken a CFTR modulator within 30 days prior to initial dose of study drugs
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   Denmark,   Germany,   Sweden,   United States
Removed Location Countries Portugal
 
Administrative Information
NCT Number  ICMJE NCT03140527
Other Study ID Numbers  ICMJE PTI-801-01
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Proteostasis Therapeutics, Inc.
Study Sponsor  ICMJE Proteostasis Therapeutics, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Proteostasis Therapeutics, Inc.
Verification Date April 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP